Mercator Medsystems, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2000-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.mercatormed.com
Clinical Trials
11
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT
- Conditions
- Thrombosis, Deep VeinIliofemoral; Thrombosis
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Mercator MedSystems, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT04862468
- Locations
- 🇺🇸
Baptist Health, Jacksonville, Florida, United States
🇺🇸Piedmont Heart Institute, Atlanta, Georgia, United States
🇺🇸Englewood Health, Englewood, New Jersey, United States
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT
- Conditions
- Iliofemoral; Thrombosis
- First Posted Date
- 2021-04-26
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Mercator MedSystems, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04858776
- Locations
- 🇺🇸
Vascular Care Connecticut, Darien, Connecticut, United States
🇺🇸University of South Florida, Tampa, Florida, United States
🇺🇸Northwestern University Hospital, Chicago, Illinois, United States
Temsirolimus Adventitial Delivery to Improve ANGioplasty And/or Atherectomy Revascularization Outcomes Below the Knee
- Conditions
- Peripheral Artery DiseaseCritical Limb Ischemia
- Interventions
- Drug: Saline placebo
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Mercator MedSystems, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT04433572
Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
- Conditions
- Peripheral Arterial Disease
- Interventions
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Mercator MedSystems, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03942601
- Locations
- 🇺🇸
Arkansas Heart Hospital, Little Rock, Arkansas, United States
🇺🇸St. Joseph Hospital of Orange Heart and Vascular Center, Orange, California, United States
🇺🇸San Francisco VA Medical Center, San Francisco, California, United States
Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO)
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Mercator MedSystems, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT02908035
- Locations
- 🇺🇸
Arkansas Heart Hospital, Little Rock, Arkansas, United States
🇺🇸St. Joseph Hospital of Orange Heart and Vascular Center, Orange, California, United States
🇺🇸Denver Veterans Administration Hospital, Denver, Colorado, United States
- Prev
- 1
- 2
- Next